Issue Date: May 14, 2013
A vaccine against rotavirus infection, developed in India as a low-cost alternative to available vaccines, has shown positive results in Phase III clinical trials. Rotavirus is the most severe and lethal cause of childhood diarrhoea, and is responsible for the death of approximately 100,000 small children in India each year. The vaccine, Rotavac, developed as part of a public-private partnership endeavour, will cost about 50 times less than currently available vaccines.
See also:
function rotavirus()
{
var popurl="http://www.downtoearth.org.in/themes/DTE/htm/rotavirus.htm"
winpops=window.open(popurl,"","width=520,height=460,scrollbars=yes")
}
A brief profile of rotavirus
Resources from the IEP
A brief profile of rotavirus
Direct costs of hospitalization for rotavirus gastroenteritis in different health facilities in India
India leads in rotavirus infection deaths: Lancet
Vaccine campaign to target deadly childhood diarrhoea